These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10738247)

  • 21. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
    Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
    Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
    Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.
    Kuvaja P; Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
    Hum Pathol; 2006 Oct; 37(10):1316-23. PubMed ID: 16949931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer.
    Patel BP; Shah SV; Shukla SN; Shah PM; Patel PS
    Head Neck; 2007 Jun; 29(6):564-72. PubMed ID: 17252594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.
    Remacle AG; Noël A; Duggan C; McDermott E; O'Higgins N; Foidart JM; Duffy MJ
    Br J Cancer; 1998 Mar; 77(6):926-31. PubMed ID: 9528836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The matrix metalloproteinase system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2006 Dec; 44(6):482-6. PubMed ID: 16338034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plantamajoside, a potential anti-tumor herbal medicine inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of matrix metalloproteinase-9 and -2.
    Pei S; Yang X; Wang H; Zhang H; Zhou B; Zhang D; Lin D
    BMC Cancer; 2015 Dec; 15():965. PubMed ID: 26674531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gelatinolytic activity of matrix metalloproteinase-2 and matrix metalloproteinase-9 in rat brain after implantation of 9L rat glioma cells.
    Zhao JX; Yang LP; Wang YF; Qin LP; Liu DQ; Bai CX; Nan X; Shi SS; Pei XJ
    Eur J Neurol; 2007 May; 14(5):510-6. PubMed ID: 17437609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Activity of matrix metalloproteinases -2 and -9 (MMP-2 and MMP-9) and content of their tissue inhibitors in endometrial cancer--a preliminary study].
    Bogusiewicz M; Stryjecka-Zimmer M; Rechberger T
    Ginekol Pol; 2007 May; 78(5):366-72. PubMed ID: 17867327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera.
    La Rocca G; Pucci-Minafra I; Marrazzo A; Taormina P; Minafra S
    Br J Cancer; 2004 Apr; 90(7):1414-21. PubMed ID: 15054465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors.
    Määttä M; Santala M; Soini Y; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
    Tumour Biol; 2004; 25(4):188-92. PubMed ID: 15557756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
    Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation.
    Wang F; Reierstad S; Fishman DA
    Cancer Lett; 2006 May; 236(2):292-301. PubMed ID: 16019136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
    Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
    Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matrix metalloproteinase-2 and -9 involvement in canine tumors.
    Loukopoulos P; Mungall BA; Straw RC; Thornton JR; Robinson WF
    Vet Pathol; 2003 Jul; 40(4):382-94. PubMed ID: 12824510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis.
    Waas ET; Wobbes T; Lomme RM; DeGroot J; Ruers T; Hendriks T
    Br J Surg; 2003 Dec; 90(12):1556-64. PubMed ID: 14648736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
    Baker EA; Bergin FG; Leaper DJ
    Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measuring gelatinase activity in colorectal cancer.
    Baker EA; Leaper DJ
    Eur J Surg Oncol; 2002 Feb; 28(1):24-9. PubMed ID: 11869009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.